Targeting novel antigens for prostate cancer treatment: Focus on prostate-specific membrane antigen

Expert Opinion on Therapeutic Targets

Volumn 9, Issue 3, 2005, Pages 561-570

  Slovin, Susan F ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antigen; Immunotherapy; Prostate specific antigen (PSA); Prostate specific membrane antigen (PSMA); Vaccine; Vector

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ALUMINUM HYDROXIDE; CANCER VACCINE; CAPROMAB PENDETIDE IN 111; CARBOHYDRATE ANTIGEN; CYTOKINE; DENDRITIC CELL VACCINE; DIMER; DNA VACCINE; DOCETAXEL; ESTRAMUSTINE; GLUCOCORTICOID; GLYCOPROTEIN; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HYBRID PROTEIN; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; MEMBRANE PROTEIN; MITOXANTRONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IN 111; PREDNISONE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN; QS 21; VIRUS VACCINE;

ANTIGEN EXPRESSION; BACTERIOPHAGE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL POPULATION; CELL SURFACE; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG DESIGN; DRUG TARGETING; EFFECTOR CELL; HUMAN; HUMORAL IMMUNITY; IMMUNOTHERAPY; ISOTOPE LABELING; NEUTROPENIA; NONHUMAN; PROSTATE CANCER; PROTEIN FUNCTION; REPLICON; REVIEW; TUMOR VASCULARIZATION;

ANTIGENS, SURFACE; CANCER VACCINES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS;

EID: 21244495675     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.9.3.561     Document Type: Review

References (52)

1. TANNOCK IF, OSOBA D, STOCKLER MR et al.: Chemotherapy with mitoxantrone plus prednisone or prednisonealone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. (1996) 14:1756-1764.
2. KANTOFF PW, HALABI S, CONAWAY M et al.: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J. Clin. Oncol. (1999) 17:2506-2513.
3. TANNOCK IF, DE WIT R, BERRY WR et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. (2004) 351:1502-1512
4. PETRYLAK DP, TANGEN CM, HUSSAIN MH et al.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. (2004) 351:1513-1520.
5. BURCH PA, CROGHAN GA, GASTINEAU DA et al.: Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase II trial. Prostate (2004) 60:197-204.
6. KYLSTRA JW, NEMUNAITIS J, SMALL EJ, JONES LA: A placebo-controlled Phase III trial of immunotherapy (APC8015, Provenge ®) for androgen independent prostate cancer (AIPC): Evidence that Gleason Score predicts immunologic as well as clinical responses to therapy. Proc. Am. Assoc. Cancer Res. (2004) 45:? Abstract 1408.
7. SIMONS J, HIGANO C, CORMAN J et al.: A Phase I/II study of high dose allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:166 Abstract 667.
8. SIMONS J, NELSON W, NEMUNAITIS J et al.: Phase II trials of a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX) in hormone refractory prostate cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:183a Abstract 729.
9. SLOVIN SF, RAGUPATHI G, MUSSELLI C et al.: Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. J. Clin. Oncol. (2003) 21:4292-4298.
10. SLOVIN S, RAGUPATHI G, CLARKE T et al.: Multivalency in a Phase II prostate cancer (PC) vaccine trial: Are more antigens better? Proc. Am. Soc. Clin. Oncol. (2003) 22:167 Abstract 671.
11. SLOVIN SF, RAGUPATHI G, MUSSELLI C et al.: Thomsen-Friedenreich. Cancer Immun. Immunother. In press.
12. KAUFMAN HL, WANG W, MANOLA J et al.: Prime/boost vaccination using poxviruses expressing PSA in D0 prostate cancer: preliminary results of ECOG 7897, a randomized Phase II clinical trial. Proc. Am. Soc. Clin. Oncol. (2002) 21:4a Abstract 12.
13. SCHER HI, EISENBERGER M, D'AMICO AV et al.: Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J. Clin. Oncol. (2004) 22:537-556.
14. HINKLE GH, BURGERS JK, NEAL CE et al.: Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer (1998) 83:739-747.
15. GHOSH H, HESTON WDW: Tumor target Prostate Specific Membrane Antigen (PSMA) and its regulation in prostate cancer. J. Cell. Biochem. (2004) 91:528-539.
16. SCHULKE N, VARLAMOVA OA, DONOVAN GP et al.: The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc. Natl. Acad. Sci. USA (2003) 100:12590-12595.
17. SILVER DA, PELLICER I, FAIR WR et al.: Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. (1997) 3:81-85.
18. SU SL, HUANG IP, FAIR WR et al.: Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res. (1995) 55:1441-1443.
19. CHANG SS, REUTER VE, HESTON WD, GAUDIN PB: Metastatic renal cell carcinoma neovasculature expresses prostate specific membrane antigen. Urology (2001) 57:801-805.
20. CHANG SS, REUTER VE, HESTON WD et al.: Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. (1999) 59:3192-3198.
21. DIVGI CR, BANDER NH, SCOTT AM et al.: Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin. Cancer Res. (1998) 4:2729-3279.
22. CHANG SS, O'KEEFE DS, BACICH DJ et al.: Prostate-specific membrane antigen is produced in rumor-associated neovasculature. Clin. Cancer Res. (1999) 5:2674-2681.
23. BANDER NH, TRABULSI EJ, KOSTAKOGLU L et al.: Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J. Urol. (2003) 170:1717-1721.
24. SMITH-JONES PM, VALLABAHAJOSULA S, GOLDSMITH SJ et al.: In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. (2000) 60:5237-5243.
25. MILOWSKY MI, NANUS DM, KOSTAKOGLU L et al.: Phase I trial of yttrium-90-labeled anti-proscate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J. Clin. Oncol. (2004) 22:2522-2531.
26. NANUS DM, MILOWSKY MI, KOSTAKOGLU L et al.: Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J. Urol. (2003) 170:S84-S88.
27. TJOA BA, SIMMONS SJ, ELGAMA A et al.: Follow-up evaluation of a Phase II prostate cancer vaccine trial. Prostate (1999) 4:125-129.
28. GONG MC, LATOUCHE JB, KRAUSE A et al.: Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia (1999) 1:123-127.
29. O'KEEFE DS, UCHIDA A, BACICH D et al.: Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate (2000) 45:149-157.
30. GONG MC, CHANG SS, WATT F et al.: Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy. Mol. Urol. (2000) 4:217-222.
31. UCHIDA A, O'KEEFE DS, BACICH DJ et al.: In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy. Urology (2001) 85:132-139.
32. MINCHEFF M, ALTANKOVA I, ZOUBAK S et al.: In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer - changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-gamma lymphokine profile. Crit. Rev. Oncol. Hematol. (2001) 39:125-132.
33. LU J, CELLIS E: Recognition of prostate tumor cell by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res. (2002) 62:5807-5812.
34. KURATSUKURI K, SONE T, WANG CT et al.: Inhibition of prostate specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA. Int. J. Cancer (2002) 102:244-249.
35. MINCHEFF M, ZOUBAK S, ALTANKOVA I et al.: Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes. Cancer Gene Ther. (2003) 10:907-917.
36. MINCHEFF M, TCHAKAROV S, ZOUBAK S et al.: Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a Phase I/II clinical trial. Eur. Urol. (2000) 38:208-217.
37. HORIGUCHI Y. NUKAYA I, OKAZAWA K et al.: Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes. Clin. Cancer Res. (2002) 8:3885-3892.
38. MURPHY GP, TJOA BA, SIMMONS SJ et al.: Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients. Prostate (2000) 43:59-62.
39. ANILKUMAR G, RAJASEKARAN SA, WANG S et al.: Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity. Cancer Res. (2003) 63:2645-2648.
40. BACICH DJ, PINTO JT, TONG WP, HESTON WD: Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm. Genome (2001) 12:117-123.
41. YAO R, SCHNEIDER E, RYAN TJ et al.: Human gamma-glutamyl hydrolase: cloning and characterization of the enzyme expressed in vitro. Proc. Natl. Acad. Sci. USA (1996) 93:10134-10138.
42. TASCH J, GONG M, SADELAIN M, HESTON WD: A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit. Rev. Immunol. (2001) 21:249-261.
43. LIU H, RAJASEKARAN AK, MOY P et al.: Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. (1998) 58:4055-4060.
44. SLOVIN SF: Vaccines as treatment strategies for relapsed prostate cancer: approaches for induction of immunity. Hematol. Oncol. Clin. North. Am. (2001) 15:477-496
45. SLOVIN SF, SCHER HI: Peptide and carbohydrate vaccines in relapsed prostate cancer: immunogenicity of synthetic vaccines in man-clinical trials at Memorial Sloan-Kettering Cancer Center. Semin. Oncol. (1999) 26:448-454.
46. WOLCHOK JD, GREGOR PD, NORDQUIST LT et al.: DNA vaccines: an active immunization strategy for prostate cancer. Sem. Oncol. (2003) 30:659-666.
47. GREGOR PD, WOLCHOK JD, FERRONE CR et al.: CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine (2004) 22:1700-1708.
48. FONG L, RUEGG CL, BRICKSTEDT D et al.: Induction of tissue specific autoimmune prosuatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. Cancer Res. (1999) 59:3102-3198.
49. GARDNER JP, SLOVIN SF, MORRISSEY DM et al.: Recombinant soluble prostate-specific membrane antigen (rsPSMA) vaccine: preliminary findings of a Phase I safety/immunogenicity trial. Proc. Am. Soc. Clin. Onc. (2004) 23:184 Abstract 2584.
50. GARDNER JP, DONOVAN GP, SCHUELKE N et al.: Active tumor immunotherapy using novel PSMA-based alphavirus and protein vaccines. Proc. Am. Assoc. Cancer Res. (2003) 44:1088 Abstract 4747.
51. VELDERS MP, MCELHINEY S, CASSETTI MC et al.: Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavurus 16 E7 RNA. Cancer Res. (2001) 61:7861-7867.
52. DAVIS NL, CALEY IJ, BROWN KW et al.: Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J. Virol. (2000) 74:371-378.